Breast Cancer: 45 Years of Research and Progress.

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Journal of Clinical Oncology

• Publication date

  2020-04-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.20.00199PMID 32255711PMCID PMC9798921
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.

  2019cited by this paper
• Cancer statistics, 2019

  2019cited by this paper
• Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer

  2019cited by this paper
• Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.

  2018cited by this paper
• MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.

  2017cited by this paper
• Adjuvant trastuzumab: a 10-year overview of its benefit

  2017cited by this paper
• Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

  2016cited by this paper
• Palbociclib and Letrozole in Advanced Breast Cancer.

  2016cited by this paper
• Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.

  2015cited by this paper
• The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

  2015cited by this paper
• Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

  2014cited by this paper
• Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

  2012cited by this paper
• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

  2011cited by this paper
• Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.

  2009cited by this paper
• Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.

  2009cited by this paper
• Current Status of Cetuximab for the Treatment of Patients with Solid Tumors

  2006cited by this paper
• Trastuzumab in the treatment of breast cancer.

  2005cited by this paper
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  2005cited by this paper
• A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

  2004cited by this paper
• Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.

  2003cited by this paper
• Total RNA yield and microarray gene expression profiles from fine‐needle aspiration biopsy and core‐needle biopsy samples of breast carcinoma

  2003cited by this paper
• Global Gene Expression Changes During Neoadjuvant Chemotherapy for Human Breast Cancer

  2002cited by this paper
• A gene-expression signature as a predictor of survival in breast cancer.

  2002cited by this paper
• Initial sequencing and analysis of the human genome

  2001cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• The sequence of the human genome (abstract only)

  2001cited by this paper
• Osteoporosis prevention, diagnosis, and therapy.

  2000cited by this paper
• Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.

  1999cited by this paper
• Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.

  1999cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

  1998cited by this paper
• Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

  1996cited by this paper
• Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.

  1996cited by this paper
• Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.

  1995cited by this paper
• Oligometastases.

  1995cited by this paper
• American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.

  1994cited by this paper
• Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.

  1991cited by this paper
• Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.

  1989cited by this paper
• Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy.

  1988cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist.

  1987cited by this paper
• Sequence the Human Genome

  1986cited by this paper
• Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer.

  1985cited by this paper
• The preclinical new drug research program of the National Cancer Institute.

  1984cited by this paper
• Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody.

  1983cited by this paper
• Multimodal treatment of locoregionally advanced breast cancer

  1983cited by this paper
• Portable infusion pumps in ambulatory cancer chemotherapy

  1982cited by this paper
• Management of inflammatory carcinoma of breast with combined modality approach—an update

  1981cited by this paper
• Autologous bone marrow transplantation in neoplasia.

  1981cited by this paper
• Angioaccess in cancer patients.

  1981cited by this paper
• Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED)

  1979cited by this paper
• Long-term human breast carcinoma cell lines of metastatic origin: Preliminary characterization

  1978cited by this paper
• Specific radiolabeling of a cell surface receptor for epidermal growth factor.

  1977cited by this paper
• Combination chemotherapy as an adjuvant treatment in operable breast cancer.

  1976cited by this paper
• CRITICAL REVIEW OF PREVIOUSLY REPORTED CLINICAL TRIALS OF CANCER IMMUNOTHERAPY WITH NON‐SPECIFIC IMMUNOSTIMULANTS *

  1976cited by this paper
• 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings.

  1975cited by this paper
• New concepts in the management of primary breast cancer

  1975cited by this paper
• Genetic study of breast cancer: Identification of a high risk group

  1974cited by this paper
• Superiority of adriamycin over oral nitrosoureas in patients with advanced breast carcinoma. A southwest cancer chemotherapy study group study

  1974cited by this paper
• Familial association of carcinoma of the breast and ovary.

  1974cited by this paper
• The chemical therapy of breast cancer.

  1974cited by this paper
• Cancer statistics 1973

  1973cited by this paper
• Treatment of advanced mammary cancer.

  1972cited by this paper
• Oestrogen-receptor interaction in target tissues.

  1969cited by this paper

• The effect of time on associations between historical redlining and breast cancer survival

  2026cites this paper
• Trends of Female Breast Cancer Burden in China over 25 Years: A Join Point Regression and Age-Period-Cohort Analysis Based on the GBD (1997–2021)

  2025cites this paper
• Role of Oxidative Stress in the Occurrence, Development, and Treatment of Breast Cancer

  2025cites this paper
• Screening for breast cancer: a systematic review update to inform the Canadian Task Force on Preventive Health Care guideline

  2024cites this paper
• Oral Anticancer Therapies: Addressing Nonadherence in Patients With Breast Cancer.

  2024cites this paper
• Global burden and attributable risk factors of breast cancer in young women: historical trends from 1990 to 2019 and forecasts to 2030 by sociodemographic index regions and countries

  2024cites this paper
• Adjuvant or neoadjuvant therapeutic strategy for resectable non-small cell lung cancer.

  2023cites this paper
• Analysis on Incidence and Mortality Trends and Age–Period–Cohort of Breast Cancer in Chinese Women from 1990 to 2019

  2023cites this paper
• Bufalin reverses ABCB1-mediated resistance to docetaxel in breast cancer

  2023cites this paper
• Obesity and breast cancer prognosis: pre-diagnostic anthropometric measures in relation to patient, tumor, and treatment characteristics

  2023cites this paper
• Advances in Treatment and Health-Related Quality of Life: A Cohort Study of Older Adult Survivors of Breast Cancer.

  2023cites this paper
• Cytotoxicity and Radiosensitizing Potentials of Pilosulin-3, a Recombinant Ant Venom, in Breast Cancer Cells

  2023cites this paper
• Forty-Five Years of Research and Progress in Breast Cancer: Progress for Some, Disparities for Most

  2022cites this paper
• Under-served groups remain underserved as eligibility criteria routinely exclude them from breast cancer trials.

  2022cites this paper
• Risk of primary haematologic cancers following incident non-metastatic breast cancer: A Danish population-based cohort study.

  2022cites this paper
• NR4A1 Ligands as Potent Inhibitors of Breast Cancer Cell and Tumor Growth

  2021cites this paper
• Clinical Perspectives in Addressing Unsolved Issues in (Neo)Adjuvant Therapy for Primary Breast Cancer

  2021cites this paper
• Mitochondrial Fission Regulator 2 (MTFR2) Confers anti-ER Endocrine Therapy Resistance to Breast Cancer Cells by Modulating Mitochondrial Autophagy through Direct Phosphorylation of FUNDC1

  2021influential citation
• Yap-Hippo Signaling Activates Mitochondrial Protection and Sustains Breast Cancer Viability under Hypoxic Stress

  2021cites this paper
• Female Breast Cancer Treatment and Survival in South Australia: Results from Linked Health Data

  2020cites this paper
• Female breast cancer treatment and survival in South Australia: Results from linked health data

  2020cites this paper
• Minimal Residual Disease in Patients With Nonmetastatic Triple-Negative Breast Cancer: Positive, Negative, or a More Complex Issue?

  2020cites this paper
• Landmark trials in the medical oncology management of early stage breast cancer.

  2020cites this paper